Skip to main content
. 2024 Feb 7;12(3):e02872-23. doi: 10.1128/spectrum.02872-23

TABLE 2.

Relative sensitivity for ≥CIN2 and ≥CIN3 and specificity for ≤CIN1 of Onclarity assay on self-collected compared to clinician-taken samples

Sample type Relative sensitivity
(95% CI) ≥CIN2
Relative sensitivity
(95% CI )≥CIN3
Relative specificity
(95% CI )≤CIN1
1st vaginal 1.01 (0.97–1.06) 1.00 (0.94–1.06) 0.83 (0.73–0.94)
2nd vaginal (BD Viper LT) 1.01 (0.97–1.06) 1.00 (0.94–1.06) 0.76 (0.67–0.87)
2nd vaginal (BD COR) 1.00 (0.95–1.05) 0.98 (0.90–1.06) 0.82 (0.73–0.92)